Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-24.35% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Sep 30, 2023
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001600620-23-000044General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
-2.27% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
60.20% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
87.58% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-29.83% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
24.96% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
21.66% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -6.81%
- Current
- -24.35%
- Delta
- -17.54%
- Previous
- 47.19%
- Current
- -2.27%
- Delta
- -49.45%
- Previous
- 79.90%
- Current
- 60.20%
- Delta
- -19.70%
- Previous
- 96.23%
- Current
- 87.58%
- Delta
- -8.65%
- Previous
- -38.97%
- Current
- -29.83%
- Delta
- 9.14%
- Previous
- 30.49%
- Current
- 24.96%
- Delta
- -5.53%
- Previous
- 29.57%
- Current
- 21.66%
- Delta
- -7.91%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_DECREASED →Transitioned To · AUPH GROWTH_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_DECREASED →Transitioned To · AUPH MARGIN_DECREASED →Transitioned To · AUPH PROFITABILITY_INCREASED →Transitioned To · AUPH R_AND_D_INTENSITY_DECREASED →Transitioned To · AUPH SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.